[ad#PhycoBiosciences AIM Interview]

Innovations

Sealantis’ alga-mimetic sealant in clinical study

July 22, 2013
AlgaeIndustryMagazine.com

Seal-1

Haifa, Israel-based Sealantis Ltd., a private start-up emerging from the Technion-Israel Institute of Technology, reports that eight patients have now been treated with Seal-V, its alga-mimetic vascular sealant, as part of the company’s first clinical study.

Seal-V is a protein-free sealant, designed to resolve current limitations and challenges in the control of surgical bleeding. The clinical trial, taking place in Israel, is evaluating the safety and efficacy of achieving hemostasis in large peripheral blood vessels using the Seal-V protein-free sealant.

Sealantis is a 6-year-old startup, located on the campus of one of Israel’s leading academic centers — the Technion. Sealantis was founded by Prof. Havazelet Bianco-Peled, a world-renowned expert in biomedical polymers.

Since the early 2000s, Prof. Bianco-Peled had been researching the adhesion mechanism of algae to rocks underwater. The research unveiled the chemical composition of the algae adhesive, but it was the professor’s invention of a synthetic, alga-mimetic adhesive that enabled harnessing nature’s power for practical and commercial uses.

Seal-2

In 2007, the invention was embraced by the Alfred Mann Institute at the Technion (AMIT), which is funding the company. While having potential uses in a variety of industrial applications, Sealantis chose to focus on urgent medical needs –  controlling leakage of body fluids through surgical or traumatic wounds. Such leaks can be fatal since sutures or staples are not fully leak-proof. “Sealing surgical incisions requires sticking to wet or moist surfaces, which is a challenge that most known adhesives can’t usually meet,” said Prof. Bianco-Peled.

Surgical sealants represent a market of over $1.0 billion, which grows 14% annually. “When I look at the market, it’s clear to me that there is no single winning solution,” says Dr. Zeev Gilkis, AMIT CEO and Sealantis Ltd. Chairman. “There are some good products, but each one has drawbacks or is limited to a specific application. Sealantis brings a versatile yet simple technology, addressing unmet clinical needs.”

“Seal-V is overcoming a clinical need with its unique features, which offer simultaneous sealing and hemostasis for native and synthetic vascular fields,” said Prof. Vincent Riambau, Chief of Vascular Surgery Division, Hospital Clínic, University of Barcelona, and Past President of the European Society of Vascular Surgery (ESVS), who serves on the Clinical Advisory Board of Sealantis. “It is accomplishing valuable qualities for vascular surgery, being quick, easy to use, effective and safe. It will surely be most welcome to the vascular community.”

Sealantis Ltd. is currently planning its next regulatory steps toward a PMA study and FDA approval of Seal-V and is working on strategic partnerships towards the coming market launch.”

More Like This…

HOME Algae Industry Jobs

Copyright ©2010-2013 AlgaeIndustryMagazine.com. All rights reserved. Permission granted to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

From The A.I.M. Archives

— Refresh Page for More Choices
A new $1 million relationship between Michigan State University and ExxonMobil will expand research in the fundamental science to advance algae-based fuels. Dr. David Kra...
The Chesapeake Bay Seed Capital Fund, located in College Park, Maryland, has invested $150,000 into Manta Biofuel LLC, a company that produces crude oil from algae at a c...
The Technical University of Munich (TUM) has built a one-of-a-kind technical facility for algae cultivation at the Ludwig Bölkow Campus in Ottobrunn, to the south of Muni...
The Symbiosis Center in Denmark is exploring the industrial potential of microalgae, reports EUobserver's Regional Focus magazine. Using CO2 and light to produce valuable...
Hannah Osborne writes in the International Business Times that algae has been genetically engineered to kill cancer cells without harming healthy cells. The algae nanopar...
The U.S. Department of Energy (DOE) has awarded Arizona State University (ASU) a three-year, $1 million grant to fund the Atmospheric Carbon Dioxide Capture and Membrane ...
Algae producers moving from pilot to commercial applications require quick adaptation to algae harvesting capacity of hundreds and even thousands of cubic meters per day....
Algatechnologies Ltd. has launched its AstaPure® 5% Natural Astaxanthin oleoresin, derived from Haematococcus pluvialis microalgae. This latest addition to the AstaPure f...
Students of algal research, including it's various applications and business models, have increasing opportunities to get quickly up to speed in many aspects of the rapid...
I’m an aquanaut teen. I was born in immersion in 2050 in an underwater farm called “Aequorea” off the coast of Rio de Janeiro. Bio-inspired, the farm draws its name from ...
Nevele, Belgium-based TomAlgae is developing freeze-dried microalgae for feed in shrimp hatcheries. The company has created its own microalgal “cultivar” and manufactures...
Flint Michigan’s water supply was switched from Lake Huron to the Flint River in 2014. The Flint is so notoriously dirty that some locals call it the Filth River. The cha...